Recently, our group has previously demonstrated the potential of autophagy marker ATG5 as a therapeutic and diagnostic biomarker, observing the autophagy marker’s increase in primary SS DE compared to non-SS DE [17,18]. This evidence concerns the gene ATG5 and synovial sarcoma.